Sunitinib malate in patients with intermediate-2 or high-risk myelodysplastic syndrome or chronic myelomonocytic leukemia.
Yee KW, Storring JM, Buckstein R, Wells RA, Xenocostas A, Kovacs MJ, Howson-Jan K, Wang ES, Battista K, Wang L, Oza AM, Ivy SP, Schuh AC.
Yee KW, et al. Among authors: wells ra.
Leuk Lymphoma. 2014 Nov;55(11):2669-71. doi: 10.3109/10428194.2014.900763. Epub 2014 Apr 22.
Leuk Lymphoma. 2014.
PMID: 24611649
Clinical Trial.
No abstract available.